Page 1 of Clinical Trials for Drug ABT-335, 20 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
Last Updated: June 3, 2009
Condition(s): Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia
2
Active, not recruiting
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
Last Updated: March 11, 2012
Condition(s): Dyslipidemia; Coronary Artery Disease; Coronary Heart Disease
3
Completed
Interaction Between ABT-335, Rosuvastatin and Warfarin
Last Updated: March 22, 2011
Condition(s): Healthy
4
Completed
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Last Updated: June 9, 2011
Condition(s): Dyslipidemias; Coronary Heart Disease; Combined (Atherogenic) Dyslipidemia; Mixed Dyslipidemia
5
Completed
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
Last Updated: March 21, 2012
Condition(s): Dyslipidemia, Renal Insufficiency
6
Completed
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
Last Updated: December 14, 2009
Condition(s): Atherogenic Dyslipidemia
7
Completed
A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
Last Updated: January 18, 2012
Condition(s): Mixed Dyslipidemia
8
Completed
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
Last Updated: September 24, 2010
Condition(s): Hypercholesterolemia; Dyslipidemia
9
Completed
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
Last Updated: June 3, 2009
Condition(s): Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia
10
Completed
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Last Updated: May 29, 2009
Condition(s): Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia
11
Completed
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
Last Updated: October 18, 2010
Condition(s): Pharmacokinetics
12
Completed
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Last Updated: June 1, 2009
Condition(s): Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia
13
Completed
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Last Updated: October 19, 2010
Condition(s): Healthy
14
Completed
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
Last Updated: October 19, 2010
Condition(s): Healthy
15
Completed
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
Last Updated: October 14, 2010
Condition(s): Adverse Events; Pharmacokinetic
16
Completed
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
Last Updated: September 26, 2011
Condition(s): Dyslipidemias; Coronary Heart Disease; Kidney Disease
17
Completed
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.
Last Updated: October 19, 2010
Condition(s): Adverse Events; Pharmacokinetic Variables
18
Completed
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
Last Updated: March 25, 2011
Condition(s): Dyslipidemia
19
Completed
Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules
Last Updated: October 14, 2010
Condition(s): Healthy
20
Terminated
Study of Trilipix Effects on Lipids and Arteries
Last Updated: July 27, 2011
Condition(s): Dyslipidemia

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+ABT-335

Page 1 of Clinical Trials for Drug ABT-335, 20 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About